Whit Bernard, Co-Founder and Chief Executive Officer of Metsera, said: Since our founding in 2022, Metsera has worked tirelessly to reduce the physical, emotional, and economic burdens of obesity
10.1152/jappl.1999.87.4.1381 42
To determine if you qualify to take legal action, it is strongly recommended that you seek consultation from an attorney
[19] has shown that patients receiving GLP-1RA for T2DM have had fat and muscle loss compared to patients receiving placebo
Nearly 22% of adults find it very difficult to afford GLP-1 treatments, highlighting affordability as a significant barrier to access, which affects awareness and utilization across different income levels
The Discovery and Development of Liraglutide and Semaglutide